What is the role of non-surgical chin augmentation in full-face rejuvenation?
What can dermatologists learn about new modalities for the sagging neck?
What new developments in injectable fillers were discussed at the AAD 2019 Annual Meeting?
Hassan I. Galadari, MD, FAAD
UAE University, Abu Dhabi, United Arab Emirates
Fillers, cosmetic dermatology
When considering dermal fillers, what concerns are most important for you as a dermatologist, and for your patients?
What cosmetic dermatology advances are of greatest interest to dermatologists, researchers, and patients?
What trends in cosmetic dermatology did you see in 2018, and what do you anticipate for 2019?
Brian A. Ginsberg, MD, FAAD
Icahn School of Medicine at Mount Sinai, New York, NY, USA
What dermatology issues are particularly relevant to transgender patients?
What management challenges do you encounter when treating transgender patients?
Is it possible that dermatology procedures currently deemed cosmetic or elective will be considered medically necessary for transgender patients in the future?
Nellie Konnikov, MD, FAAD
Boston University School of Medicine, Boston, MA, USA
Field cancerization therapies, photodynamic therapy
What can dermatologists learn about field cancerization therapies at the 2019 AAD Annual Meeting?
Can photodynamic therapy be a useful modality for field cancerization in elderly and high-risk immunosuppressed patients?
What new developments in photodynamic therapy are featured at the AAD 2019 Annual Meeting, and how can dermatologists use this knowledge to improve patient care?
How are photodynamic therapy candidates selected, and how are therapeutic goals set?
Mark G. Lebwohl, MD, FAAD
Icahn School of Medicine at Mount Sinai, New York, NY, USA
Psoriasis, psoriatic arthritis
What are the best methods for determining which drug is best suited for the specific patient?
What are new developments in the treatment of psoriatic arthritis?
Boris D. Lushniak, MD, MPH, FAAD
School of Public Health, University of Maryland, College Park, MD, USA
The dermatologist in modern society
What topics does the AAD 2019 Annual Meeting cover about the changing role of the dermatologist in contemporary society?
How might dermatologists influence the way that health systems provide patient care?
How can dermatologists balance the challenges of applying technical advances, containing costs, and improving outcomes to provide high-quality patient care?
Crystal L. Mackall, MD
Stanford University, Stanford, CA, USA
Engineering T cells for cancer therapy
After many decades of research, genetically engineered T cells are demonstrating unprecedented activity against B-cell malignancies. Could the engineered immune cells also prove effective against solid tumors?
What is the current state-of-the-art of engineered immune cells for the treatment of cancer?
Antigen escape and downregulation have emerged as major issues impacting the durability of CAR T cell therapy. What is their incidence and what are the ways to overcome these obstacles in order to improve clinical outcomes?
Kristian Reich, MD, PhD
University Medical Center Hamburg-Eppendorf, Germany
Psoriasis, atopic dermatitis
What are your highlights from the AAD 2019 Annual Meeting in the areas of psoriasis and atopic dermatitis?
Jerry Shapiro, MD, FAAD
NYU Langone Medical Center, New York, NY, USA
What are new developments for the quantification of progress when evaluating patient outcomes?
What emerging therapies to treat hair loss were presented at the AAD 2019 Annual Meeting?
How does treating hair loss in women differ from treating hair loss in men?
How does the cause of hair loss impact the treatment options considered by physician and patient?
Daniel M. Siegel, MD, MS, FAAD
SUNY Downstate Medical Center University, Brooklyn, NY, USA
Dermatologic surgery pearls: optimizing safety, satisfaction, efficiency
What technological innovations were discussed at the AAD 2019 Annual Meeting?
What are some valuable opportunities for AAD member dermatologists to collaborate with international colleagues to improve clinical practice?
How can dermatologists enhance patient safety and patient-centered outcomes?
Jashin J. Wu, MD, FAAD
Dermatology Research and Education Foundation, Irvine, CA, USA
Joint AAD-NPF Psoriasis Guidelines
What are some updates on the 2019 Joint American Academy of Dermatology-National Psoriasis Foundation (AAD-NPF) Psoriasis Guidelines?
In what ways do the 2019 Joint AAD-NPF Psoriasis Guidelines differ from previous guidelines?
Professional speaker, career coach & entrepreneur, Palo Alto, CA, USA
Patient empowerment in the digital age
We live in times of great social, scientific, and technological transformation. Do you think that it's possible to dismantle, then redesign existing healthcare systems?
How can physicians help patients understand the current medical revolution driven by innovative technologies?
Patients have traditionally been passive. In your book, The Patient as CEO, you describe technologies disrupting medicine, putting patients in control of their own healthcare. How will this impact the future of medicine?
Prof. Piergiacomo Calzavara-Pinton
Ricerca, dermatite atopica, psoriasi, cheratosi attinica e tumori cutanei
Qual è lo stato della ricerca dermatologica in Italia? E quale attenzione ha l’innovazione in dermatologia nel nostro paese?
Qual è oggi il ruolo delle società scientifiche nella gestione e nella programmazione della sanità?
AAD 2019: quali novità per il trattamento della dermatite atopica nell’adulto e nel bambino?
Quali ulteriori sviluppi nella terapia della psoriasi?
Psoriasi e dermatite atopica: qual è il percorso dei pazienti nell’era dei biologici?
AAD 2019: cosa c’è di nuovo per il trattamento della cheratosi attinica e dei tumori cutanei?
Prof. Antonio Costanzo
Humanitas University, Milano
Psoriasi, medicina personalizzata
Il trattamento della psoriasi offre molti strumenti terapeutici: come scegliere quello giusto?
Cosa sappiamo sull’impatto genetico della psoriasi sulla risposta al trattamento?
La farmacogenomica potrebbe aiutare il dermatologo nella scelta del farmaco giusto per il paziente giusto?
La "drug survival" è una misura utile dell’efficacia della terapia biologica per la psoriasi nella pratica quotidiana?
È arrivato il tempo della "medicina personalizzata" anche in dermatologia?
Quali novità per la psoriasi dall’AAD 2019?
Prof.ssa Bianca Maria Piraccini
Università di Bologna
Alopecia iatrogena permanente: quali novità?
Alopecia areata: quali i nuovi farmaci?
Unghie quale segno di malattie sistemiche: come e perché?
Rapporto dermatologo-oncologo: un nuovo paradigma per un futuro che è già presente?